Science Corporation, the brain-computer interface (BCI) company founded by Neuralink co-founder Max Hodak, has raised a $400 million Series D. TechCrunch reported on November 17 that the round values the company at $3.5 billion, citing a person familiar with the deal. Science announced the round in a blog post, per TechCrunch. Investors named include Khosla Ventures, the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator and PLC Neurotech.
Why it matters: unlike most BCI companies, Science already has a product that can be sold. Its PRIMA retinal implant received a CE mark in Europe in July. This round is mainly about turning that into a business on both sides of the Atlantic, and about funding a much riskier brain-sensor programme. It's also a big jump in pace: the company raised $230 million as recently as March.
The numbers
| Item | What's reported |
|---|---|
| Round | $400M Series D (TechCrunch, The Next Web) |
| Valuation | $3.5B, per one unnamed source (TechCrunch). Not confirmed by the company in what we read |
| Previous round | $230M Series C, March 5, 2026, which took the total raised since 2021 to about $490M (Science) |
| Total raised | "More than $900m" since 2021, per The Next Web. Our sum of the two figures above is about $890M, so the exact total is unclear |
| Named investors | Khosla, Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator, PLC Neurotech |
We couldn't read Science's own Series D post. The amount, valuation and investor list above come from TechCrunch and outlets citing it.
What PRIMA is, and what the evidence says
PRIMA treats geographic atrophy, the advanced "dry" form of age-related macular degeneration that destroys central vision. A photovoltaic chip measuring 2 × 2 mm sits under the retina. The patient wears special glasses that project near-infrared light onto it, and the chip turns that light into electrical stimulation. A zoom feature lets users magnify letters, according to Science.
The evidence comes from a trial of 38 patients at 17 sites in five countries, published in the New England Journal of Medicine. Science and Medical Design & Development report these results:
- 80% of patients improved by at least 0.2 logMAR (about 10 letters) at 12 months
- a mean gain of 25.5 letters on the ETDRS eye chart
- 84% could read letters, numbers and words
Science also says patients' remaining natural vision did not decline on average. The trial is small, and the sources we read don't report adverse events. That will matter to regulators and to buyers.
Regulatory status: The CE mark, issued by DEKRA under the EU's Medical Device Regulation, allows sales in 30 European countries. Science calls PRIMA the first BCI with a CE mark for "form vision," meaning reading letters and words. TechCrunch and The Next Web say it is currently available in Germany. In the US, PRIMA has FDA Breakthrough Device and Humanitarian Use Device designations, per Science.
The US route: why "humanitarian" matters
The Next Web and TechCrunch report that Science persuaded the FDA that advanced macular degeneration in both eyes is uncommon enough to qualify for a Humanitarian Device Exemption (HDE). That is a route reserved for conditions affecting relatively few patients, so expect the US label to be narrower than Europe's: TechCrunch says the FDA was persuaded on the basis that the condition is uncommon enough to qualify. No US launch date or price has been announced in the reports we read.
Where the rest of the money goes
- Europe: expanding PRIMA beyond Germany. Science said in July that reimbursement applications and clinic activations were underway.
- New indications: PRIMA is being trialled in Stargardt disease, Hodak said at TechCrunch Disrupt.
- Biohybrid brain sensor: Science's longer-term bet is a brain interface that combines lab-grown neurons with silicon. It is designing first human trials with Yale neurosurgeon Murat Günel, with Parkinson's disease among the possible uses, per TechCrunch. No timeline was given.
What to watch
- The FDA decision on the HDE application. It's the gate to US revenue, and the label wording will show how many patients qualify.
- European uptake and reimbursement. Implant volumes in Germany and whether other countries agree to reimburse will be the first real sales signal. No price has been published in the sources we read.
- Safety data at scale. As commercial implants add to the 38 trial patients, look for longer-term follow-up and complication rates.
- Whether the $3.5B figure is confirmed. For now it rests on one anonymous source.
Who should care: ophthalmologists and patients with geographic atrophy (PRIMA is the main near-term option in Europe) and investors following the BCI sector. Science's PRIMA is, by the company's account, the first BCI cleared in Europe to restore reading vision.
Sources
- TechCrunch — Science Corporation's brain tech is worth $3.5 billion after new funding techcrunch.com
- The Next Web — Max Hodak's Science raises $400m to take its sight-restoring chip to the US thenextweb.com
- Science Corporation — PRIMA receives CE mark (European launch) science.xyz
- Science Corporation — Series C announcement science.xyz
- Medical Design & Development — Brain implant restores functional vision in patients with macular degeneration medicaldesigndevelopment.com
- Startup Researcher — Science Corporation raises US$400 million Series D startupresearcher.com